Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 8546543 Fc variants that extend antibody half-life

Patent 8546543 was granted and assigned to Xencor on October, 2013 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Xencor

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

8546543

Date of Patent

October 1, 2013

Patent Application Number

13272143

Date Filed

October 12, 2011

Patent Citations Received

‌

US Patent 12103954 Heterodimeric Fc cytokines and uses thereof

‌

US Patent 11987616 Antigen binding molecules targeting SARS-CoV-2

‌

US Patent 11987617 Antibodies that target HIV GP120 and methods of use

‌

US Patent 11993644 Antigen binding molecules targeting SARS-CoV-2

‌

US Patent 11655285 Human immunodeficiency virus neutralizing antibodies

‌

US Patent 11858980 Engineered polypeptides and uses thereof

‌

US Patent 11932685 Fc variants with altered binding to FcRn

‌

US Patent 11958904 Engineered antibody Fc variants for enhanced serum half life

...

Patent Primary Examiner

‌

Chun Dahle

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8546543 Fc variants that extend antibody half-life

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API